Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals

@article{Harwood2005ImiquimodC5,
  title={Imiquimod cream 5\% for recalcitrant cutaneous warts in immunosuppressed individuals},
  author={Catherine A. Harwood and C M Perrett and Victoria L. Brown and Irene M. Leigh and Jane M. McGregor and Charlotte M. Proby},
  journal={British Journal of Dermatology},
  year={2005},
  volume={152}
}
Background  Viral warts may cause significant morbidity in individuals unable to mount an adequate T‐helper 1 cell‐mediated immune response to human papillomavirus. Imiquimod is a potent inducer of antiviral cytokine activity which has shown significant efficacy in the treatment of genital warts. Similar efficacy in cutaneous warts is not yet established. 
Successful treatment of profuse recalcitrant extra-genital warts in an HIV-positive patient using 5% imiquimod cream
  • M. Walzman
  • Medicine
  • International journal of STD & AIDS
  • 2009
TLDR
This case report highlights the successful treatment of profuse common warts of both hands and both feet in an HIV-positive patient using imiquimod 5% cream, following unsuccessful regular cryocautery therapy. Expand
Isotretinoin and candida immunotherapy for recalcitrant warts in solid organ transplant recipients
TLDR
Two cases of recalcitrant warts in SOTR successfully treated with isotretinoin in the setting of impaired renal function are provided. Expand
Successful treatment of high-grade vulval intra-epithelial neoplasia with imiquimod 5% in a renal transplant recipient
TLDR
A case of vulval intra-epithelial neoplasia in a renal transplant recipient which was successfully treated with topical imiquimod is described. Expand
Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient
  • S. Dharancy, B. Catteau, +6 authors F. Pruvot
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2006
TLDR
A case of a young liver transplant recipient who developed diffuse recalcitrant HPV‐induced warts leading to an impairment of her quality of life is reported, and significantly modified the immunosuppressive regimen. Expand
Management of cutaneous human papillomavirus infection in immunocompromised patients.
TLDR
This chapter discusses several states of immune compromise with increased susceptibility to HPV disease and reviews the literature on available management strategies including acitretin, cidofovir, Candida antigen, cimetidine, imiquimod, isotretinoin, fluorouracil, selenium, podophyllotoxin, photodynamic therapy, mammalian target of rapamycin inhibitors and the quadrivalent HPV vaccine. Expand
Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review
TLDR
There have been several studies demonstrating the successful use of imiquimod to treat recalcitrant cutaneous warts, either alone or as combination therapy, however, these studies are limited in number, include small populations, and are non-controlled. Expand
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial
Actinic keratoses (AKs) in solid organ transplant recipients (OTRs) are difficult‐to‐treat premalignancies and comparison of topical therapies is therefore warranted.
Measuring the serum level of retinol‐binding protein can enhance the treatment of recalcitrant warts
Warts are common benign (60%‐65%) self‐limited tumors of the epidermis caused by human papillomaviruses (HPVs). However, some warts fail to resolve despite of different treatments and becomeExpand
Immunotherapy for childhood warts.
TLDR
Although none of the immunologically-based treatments listed above (see Table, page 377) is FDA-approved for warts, they provide the treating physician with options for patients with warts that are resistant to standard treatments. Expand
5% Topical Imiquimod Tolerance in Transplant Recipients
TLDR
Imiquimod 5% cream is a promising, well-tolerated therapy for warts, AK and BP in transplant recipients in transplant patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients.
TLDR
2 patients on continuous immunosuppressive medication with relapsing warts resistant to topical immunotherapy with diphenylcyclopropenone (DCP) were reported on, and occlusive treatment with 5% imiquimod cream was successfully tried. Expand
Topical imiquimod for recalcitrant facial flat warts.
TLDR
A case of a 21-year-old woman who experienced complete clearance of recalcitrant facial flat warts after 3 weeks of therapy with topical imiquimod 5% cream is reported. Expand
Topical imiquimod for recalcitrant facial flat warts
TLDR
A case of a 21-year-old woman who experienced complete clearance of recalcitrant facial flat warts after 3 weeks of therapy with topical imiquimod 5% cream is reported. Expand
Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus.
TLDR
The first case of successful treatment with topical 5% imiquimod cream of facial verrucae in an individual with human immunodeficiency virus is reported. Expand
Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus
TLDR
It is felt that imiquimod could be used in HIV‐infected patients with multiple facial warts in whom conventional therapies are ineffective or produce significant side‐effects. Expand
Imiquimod; an international update on therapeutic uses in dermatology
TLDR
These properties highlight the potential of imiquimod not only as an effective treatment for genital warts, but also as a treatment for other cutaneous viral infections and cutaneous neoplasms. Expand
Treatment of genital warts with an immune-response modifier (imiquimod).
TLDR
Topical 5% imiquimod cream appears to have a significant therapeutic effect in the treatment of external genital warts, with no differences in systemic reactions or laboratory abnormalities between treatment groups. Expand
Cutaneous warts and tumours in immunosuppressed patients.
TLDR
As increasing numbers of recipients of renal allografts survive long term, complications of prolonged immunosuppression have become apparent and high rates of non-melanoma skin cancer and carcinoma of the cervix, vulva and perineum are of particular concern. Expand
Self‐administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
TLDR
Patient‐applied 5% imiquimod cream holds promise as an effective treatment of common warts and mollusca in a difficult‐to‐treat patient population. Expand
Viral warts in organ transplant recipients: new aspects in therapy
TLDR
Clinical efficacy of imiquimod has been observed for different skin lesions, including viral warts in both immunocompetent and immunosuppressed patients, including cervical cancer patients with HPV‐associated skin tumours. Expand
...
1
2
3
...